2.3.2. Thromboembolism

Direct Oral Anticoagulants (DOACs) are recommended as first line treatment over Vitamin K
antagonists (warfarin) for treatment in newly initiated patients with non-valvular atrial fibrillation
(NVAF) as per NICE NG196

Edoxaban is recommended as first line (preferred) DOAC in newly diagnosed patients with NVAF,
unless contraindicated, not tolerated or clinically inappropriate.

For NICE NG 196 and Kent & Medway Position Statement Click here